Olivier Elemento, Ph.D.

Dr. Elemento is a tenured full professor at Weill Cornell Medicine and the Director of the Caryl and Israel Englander Institute for Precision Medicine (EIPM; https://eipm.weill.cornell.edu/) since 2017. The EIPM is fundamentally multidisciplinary and draws its ~60 faculty members from nearly all basic and clinical departments at WCM. The Englander Institute's mission is to use genomics, AI and other technologies to bring highly personalized medicine to patients at NewYork Presbyterian Hospital and foster patient-centered basic and clinical research in the areas of genomics, systems biology, AI and data science. Dr. Elemento is funded by numerous NIH grants, Foundation grants, NIH contracts and industry alliances (Eli Lilly, Janssen). He has published over 280 papers in the area of precision medicine, genomics, computational biology, systems biology and drug discovery. He has led the development of novel clinical (CLIA) genomics assays including whole-exome sequencing offered to patients at WCM/NYPH and is currently leading a large multi-disease effort to bring WGS into clinical practice at WCM/NYP. He has received several external and internal awards and recognition e.g., NSF CAREER award and Opening Plenary Speaker at AACR in 2020. Dr. Elemento has mentored numerous graduate students and postdoctoral fellows who went on to have successful careers in academia and industry. Two of his students were named "Forbes 30 under 30" while in his lab. Dr. Elemento co-founded two venture capital-funded companies: Volastra Therapeutics (with Lew Cantley, Sam Bakhoum) and OneThree Biotech (with Neel Madhukar). He serves on the scientific advisory board of Volastra, OneThree Biotech as well as of Owkin, Freenome, and several other companies.